{"id":"tpc-combined-with-tislelizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TPC (a chemotherapy regimen) provides direct cytotoxic effects against cancer cells. Tislelizumab is a humanized PD-1 inhibitor that blocks the programmed death-1 checkpoint, preventing tumor cells from suppressing T-cell immunity. The combination leverages chemotherapy's direct cell-killing activity with immunotherapy's ability to reinvigorate anti-tumor immune responses.","oneSentence":"TPC combined with Tislelizumab uses chemotherapy to damage cancer cells while Tislelizumab blocks PD-1 to enhance immune recognition and attack of tumors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:54:24.153Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indication under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT06383780","phase":"PHASE3","title":"Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-15","conditions":"Nasopharyngeal Carcinoma","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TPC combined with Tislelizumab","genericName":"TPC combined with Tislelizumab","companyName":"XIANG YANQUN","companyId":"xiang-yanqun","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TPC combined with Tislelizumab uses chemotherapy to damage cancer cells while Tislelizumab blocks PD-1 to enhance immune recognition and attack of tumors. Used for Advanced or metastatic solid tumors (specific indication under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}